The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 24, 2015

Filed:

Mar. 18, 2014
Applicant:

Chase Pharmaceuticals Corporation, Washington, DC (US);

Inventors:

Thomas N. Chase, Washington, DC (US);

Kathleen E. Clarence-Smith, Washington, DC (US);

Assignee:

Chase Pharmaceuticals Corporation, Washington, DC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/42 (2006.01); A01N 43/36 (2006.01); A61K 31/44 (2006.01); A61K 31/166 (2006.01); A61K 31/445 (2006.01); A61K 31/454 (2006.01); A61K 31/55 (2006.01); A61K 45/06 (2006.01); A61K 31/27 (2006.01); A61K 31/4178 (2006.01);
U.S. Cl.
CPC ...
A61K 31/166 (2013.01); A61K 31/27 (2013.01); A61K 31/4178 (2013.01); A61K 31/445 (2013.01); A61K 31/454 (2013.01); A61K 31/55 (2013.01); A61K 45/06 (2013.01);
Abstract

There is described a method for increasing the maximal tolerated dose and thus the efficacy of an acetylcholinesterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-anticholinergic antiemetic agent, whereby an enhanced acetylcholinesterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-anticholinergic antiemetic agent for the preparation of a pharmaceutical composition for the treatment of Alzheimer type dementia in combination with an acetylcholinesterase inhibitor (AChEI) and pharmaceutical compositions comprising (a) a 5HTreceptor antagonist, a dopamine antagonist, a H1-receptor antagonist, a cannabinoid agonist, aprepitant or casopitant as an antiemetic agent and (b) an acetylcholinesterase inhibitor are also described.


Find Patent Forward Citations

Loading…